Barclays analyst Peter Lawson maintained a Buy rating on Arcellx Inc (ACLX – Research Report) today and set a price target of $115.00. The company’s shares closed yesterday at $61.39.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Lawson is an analyst with an average return of -3.2% and a 37.78% success rate. Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Syndax Pharmaceuticals, and Arvinas Holding Company.
Currently, the analyst consensus on Arcellx Inc is a Strong Buy with an average price target of $115.18.
ACLX market cap is currently $3.26B and has a P/E ratio of -80.80.
Read More on ACLX:
- Arcellx Inc’s Anito-cel: Promising Performance and Positive Outlook with Buy Rating
- Arcellx reports FY24 EPS ($2.00), consensus ($1.50)
- Arcellx Inc’s Anito-cel: A Promising Investment with Innovative Therapeutics and Market Potential
- Opco lists five potential biotech targets into JPMorgan conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue